ID   MOLM-13
AC   CVCL_2119
SY   MOLM13; Molm13; Molm 13
DR   BTO; BTO:0004175
DR   CLO; CLO_0009848
DR   AddexBio; C0003003/60
DR   ArrayExpress; E-MTAB-2770
DR   ArrayExpress; E-MTAB-3610
DR   ArrayExpress; E-MTAB-7721
DR   ArrayExpress; E-MTAB-7722
DR   BioGRID_ORCS_Cell_line; 403
DR   BioSample; SAMN03473102
DR   BioSample; SAMN10988379
DR   cancercelllines; CVCL_2119
DR   Cell_Model_Passport; SIDM00437
DR   ChEMBL-Cells; CHEMBL3706573
DR   ChEMBL-Targets; CHEMBL3706572
DR   Cosmic; 787417
DR   Cosmic; 947367
DR   Cosmic; 975274
DR   Cosmic; 996319
DR   Cosmic; 998754
DR   Cosmic; 999722
DR   Cosmic; 999772
DR   Cosmic; 1012095
DR   Cosmic; 1037671
DR   Cosmic; 1078734
DR   Cosmic; 1150897
DR   Cosmic; 1152711
DR   Cosmic; 1187863
DR   Cosmic; 1197930
DR   Cosmic; 1278778
DR   Cosmic; 1281332
DR   Cosmic; 1308222
DR   Cosmic; 1465952
DR   Cosmic; 1741687
DR   Cosmic; 1696139
DR   Cosmic; 2089664
DR   Cosmic; 2131546
DR   Cosmic; 2306220
DR   Cosmic; 2750864
DR   Cosmic; 2842299
DR   Cosmic-CLP; 1330947
DR   DepMap; ACH-000362
DR   DSMZ; ACC-554
DR   DSMZCellDive; ACC-554
DR   EGA; EGAS00001000978
DR   EGA; EGAS00001002554
DR   GDSC; 1330947
DR   GEO; GSM482509
DR   GEO; GSM887329
DR   GEO; GSM888405
DR   GEO; GSM1374688
DR   GEO; GSM1374689
DR   GEO; GSM1446738
DR   GEO; GSM1670124
DR   GEO; GSM2124117
DR   GEO; GSM2716691
DR   GEO; GSM2716692
DR   GEO; GSM2716748
DR   GEO; GSM2716749
DR   GEO; GSM2716750
DR   GEO; GSM2716751
DR   IARC_TP53; 30123
DR   JCRB; JCRB1810
DR   LiGeA; CCLE_282
DR   LINCS_LDP; LCL-1061
DR   PharmacoDB; MOLM13_950_2019
DR   PRIDE; PXD030304
DR   Progenetix; CVCL_2119
DR   PubChem_Cell_line; CVCL_2119
DR   Wikidata; Q54906320
RX   DOI=10.1016/B978-0-12-221970-2.50457-5;
RX   PubMed=9305600;
RX   PubMed=10233379;
RX   PubMed=10637496;
RX   PubMed=10739008;
RX   PubMed=11226526;
RX   PubMed=12529668;
RX   PubMed=14504097;
RX   PubMed=14671638;
RX   PubMed=15381384;
RX   PubMed=16408098;
RX   PubMed=22354205;
RX   PubMed=22460905;
RX   PubMed=23955599;
RX   PubMed=25877200;
RX   PubMed=25984343;
RX   PubMed=27397505;
RX   PubMed=27750403;
RX   PubMed=28052028;
RX   PubMed=28109323;
RX   PubMed=28196595;
RX   PubMed=29491412;
RX   PubMed=30285677;
RX   PubMed=30629668;
RX   PubMed=30894373;
RX   PubMed=31068700;
RX   PubMed=31160637;
RX   PubMed=31978347;
RX   PubMed=33669837;
RX   PubMed=35839778;
WW   https://tcpaportal.org/mclp/
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: COSMIC cell lines project.
CC   Part of: LL-100 blood cancer cell line panel.
CC   Part of: MD Anderson Cell Lines Project.
CC   Population: Japanese.
CC   Doubling time: 3-4 days (PubMed=9305600); 24 hours (PubMed=25984343); 41.1 hours (PubMed=28052028); ~50 hours (DSMZ=ACC-554).
CC   HLA typing: A*26:01:01,31:01:02; B*44:03:01,51:01:01; C*14:02:01,14:03 (DSMZCellDive=ACC-554).
CC   Microsatellite instability: Stable (MSS) (PubMed=10739008; PubMed=11226526; Sanger).
CC   Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 7136; MLLT3; Name(s)=KMT2A-MLLT3, MLL-MLLT3, MLL-AF9 (PubMed=9305600; PubMed=14671638; PubMed=15381384).
CC   Sequence variation: Mutation; HGNC; 3765; FLT3; Unexplicit; Internal tandem duplication (FLT3-ITD); ClinVar=VCV000016270; Zygosity=Unspecified (PubMed=10233379; PubMed=12529668; PubMed=27750403).
CC   Omics: H3K27ac ChIP-seq epigenome analysis.
CC   Omics: Deep exome analysis.
CC   Omics: Deep quantitative proteome analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: Protein expression by reverse-phase protein arrays.
CC   Omics: shRNA library screening.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Genome ancestry: African=0%; Native American=1.24%; East Asian, North=76.64%; East Asian, South=22.12%; South Asian=0%; European, North=0%; European, South=0% (PubMed=30894373).
CC   Derived from site: In situ; Peripheral blood; UBERON=UBERON_0000178.
ST   Source(s): AddexBio; COG; Cosmic-CLP; DSMZ; JCRB; PubMed=25877200
ST   Amelogenin: X,Y
ST   CSF1PO: 10 (AddexBio)
ST   CSF1PO: 10,12 (COG; Cosmic-CLP; DSMZ; JCRB; PubMed=25877200)
ST   D13S317: 10,11
ST   D16S539: 10,11
ST   D18S51: 13,15
ST   D19S433: 12,14
ST   D21S11: 30,31
ST   D2S1338: 23,25
ST   D3S1358: 15
ST   D5S818: 10,11
ST   D7S820: 10,12
ST   D8S1179: 13,14
ST   FGA: 21,23
ST   Penta D: 9,12
ST   Penta E: 18,19
ST   TH01: 7
ST   TPOX: 8
ST   vWA: 16,17
DI   NCIt; C9154; Adult acute myeloid leukemia
DI   NCIt; C3247; Myelodysplastic syndrome
DI   ORDO; Orphanet_519; Acute myeloid leukemia
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
OI   CVCL_7916 ! MOLM-14
SX   Male
AG   20Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 30-01-24; Version: 41
//
RX   DOI=10.1016/B978-0-12-221970-2.50457-5;
RA   Drexler H.G.;
RT   "The leukemia-lymphoma cell line factsbook.";
RL   (In) ISBN 9780122219702; pp.1-733; Academic Press; London (2001).
//
RX   PubMed=9305600; DOI=10.1038/sj.leu.2400768;
RA   Matsuo Y., MacLeod R.A.F., Uphoff C.C., Drexler H.G., Nishizaki C.,
RA   Katayama Y., Kimura G., Fujii N., Omoto E., Harada M., Orita K.;
RT   "Two acute monocytic leukemia (AML-M5a) cell lines (MOLM-13 and MOLM-14)
RT   with interclonal phenotypic heterogeneity showing MLL-AF9 fusion
RT   resulting from an occult chromosome insertion,
RT   ins(11;9)(q23;p22p23).";
RL   Leukemia 11:1469-1477(1997).
//
RX   PubMed=10233379; DOI=10.1111/j.1365-2141.1999.01284.x;
RA   Xu F., Taki T., Yang H.W., Hanada R., Hongo T., Ohnishi H.,
RA   Kobayashi M., Bessho F., Yanagisawa M., Hayashi Y.;
RT   "Tandem duplication of the FLT3 gene is found in acute lymphoblastic
RT   leukaemia as well as acute myeloid leukaemia but not in
RT   myelodysplastic syndrome or juvenile chronic myelogenous leukaemia in
RT   children.";
RL   Br. J. Haematol. 105:155-162(1999).
//
RX   PubMed=10637496; DOI=10.1038/sj.leu.2401604;
RA   Drexler H.G., Fombonne S., Matsuo Y., Hu Z.-B., Hamaguchi H.,
RA   Uphoff C.C.;
RT   "p53 alterations in human leukemia-lymphoma cell lines: in
RT   vitro artifact or prerequisite for cell immortalization?";
RL   Leukemia 14:198-206(2000).
//
RX   PubMed=10739008; DOI=10.1016/S0145-2126(99)00182-4;
RA   Inoue K., Kohno T., Takakura S., Hayashi Y., Mizoguchi H., Yokota J.;
RT   "Frequent microsatellite instability and BAX mutations in T cell acute
RT   lymphoblastic leukemia cell lines.";
RL   Leuk. Res. 24:255-262(2000).
//
RX   PubMed=11226526; DOI=10.1016/S0145-2126(00)00121-1;
RA   Inoue K., Kohno T., Takakura S., Hayashi Y., Mizoguchi H., Yokota J.;
RT   "Corrigendum to: Frequent microsatellite instability and BAX mutations
RT   in T cell acute lymphoblastic leukemia cell lines Leukemia Research 24
RT   (2000),255-262.";
RL   Leuk. Res. 25:275-278(2001).
//
RX   PubMed=12529668; DOI=10.1038/sj.leu.2402740;
RA   Quentmeier H., Reinhardt J., Zaborski M., Drexler H.G.;
RT   "FLT3 mutations in acute myeloid leukemia cell lines.";
RL   Leukemia 17:120-124(2003).
//
RX   PubMed=14504097; DOI=10.1182/blood-2003-02-0418;
RA   Taketani T., Taki T., Sugita K., Furuichi Y., Ishii E., Hanada R.,
RA   Tsuchida M., Sugita K., Ida K., Hayashi Y.;
RT   "FLT3 mutations in the activation loop of tyrosine kinase domain are
RT   frequently found in infant ALL with MLL rearrangements and pediatric
RT   ALL with hyperdiploidy.";
RL   Blood 103:1085-1088(2004).
//
RX   PubMed=14671638; DOI=10.1038/sj.leu.2403236;
RA   Drexler H.G., Quentmeier H., MacLeod R.A.F.;
RT   "Malignant hematopoietic cell lines: in vitro models for the study of
RT   MLL gene alterations.";
RL   Leukemia 18:227-232(2004).
//
RX   PubMed=15381384; DOI=10.1016/j.cancergencyto.2004.01.029;
RA   Montemurro L., Tonelli R., Fazzina R., Martino V., Marino F.,
RA   Pession A.;
RT   "Identification of two MLL-MLLT3 (alias MLL-AF9) chimeric transcripts
RT   in the MOLM-13 cell line.";
RL   Cancer Genet. Cytogenet. 154:96-97(2004).
//
RX   PubMed=16408098; DOI=10.1038/sj.leu.2404081;
RA   Quentmeier H., MacLeod R.A.F., Zaborski M., Drexler H.G.;
RT   "JAK2 V617F tyrosine kinase mutation in cell lines derived from
RT   myeloproliferative disorders.";
RL   Leukemia 20:471-476(2006).
//
RX   PubMed=22354205; DOI=10.1038/leu.2012.52;
RA   Moore A.S., Faisal A., Gonzalez de Castro D., Bavetsias V., Sun C.,
RA   Atrash B., Valenti M., De Haven Brandon A., Avery S., Mair D.,
RA   Mirabella F., Swansbury J., Pearson A.D.J., Workman P., Blagg J.,
RA   Raynaud F.I., Eccles S.A., Linardopoulos S.;
RT   "Selective FLT3 inhibition of FLT3-ITD+ acute myeloid leukaemia
RT   resulting in secondary D835Y mutation: a model for emerging clinical
RT   resistance patterns.";
RL   Leukemia 26:1462-1470(2012).
//
RX   PubMed=22460905; DOI=10.1038/nature11003;
RA   Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A.,
RA   Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A.,
RA   Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J.,
RA   Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E.,
RA   Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J.,
RA   Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C.,
RA   Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C.,
RA   Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P.,
RA   Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L.,
RA   Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M.L., Golub T.R.,
RA   Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.;
RT   "The Cancer Cell Line Encyclopedia enables predictive modelling of
RT   anticancer drug sensitivity.";
RL   Nature 483:603-607(2012).
//
RX   PubMed=23955599; DOI=10.1038/ng.2731;
RA   Kon A., Shih L.-Y., Minamino M., Sanada M., Shiraishi Y., Nagata Y.,
RA   Yoshida K.-i., Okuno Y., Bando M., Nakato R., Ishikawa S.,
RA   Sato-Otsubo A., Nagae G., Nishimoto A., Haferlach C., Nowak D.,
RA   Sato Y., Alpermann T., Nagasaki M., Shimamura T., Tanaka H., Chiba K.,
RA   Yamamoto R., Yamaguchi T., Otsu M., Obara N., Sakata-Yanagimoto M.,
RA   Nakamaki T., Ishiyama K., Nolte F., Hofmann W.-K., Miyawaki S.,
RA   Chiba S., Mori H., Nakauchi H., Koeffler H.P., Aburatani H.,
RA   Haferlach T., Shirahige K., Miyano S., Ogawa S.;
RT   "Recurrent mutations in multiple components of the cohesin complex in
RT   myeloid neoplasms.";
RL   Nat. Genet. 45:1232-1237(2013).
//
RX   PubMed=25877200; DOI=10.1038/nature14397;
RA   Yu M., Selvaraj S.K., Liang-Chu M.M.Y., Aghajani S., Busse M.,
RA   Yuan J., Lee G., Peale F.V., Klijn C., Bourgon R., Kaminker J.S.,
RA   Neve R.M.;
RT   "A resource for cell line authentication, annotation and quality
RT   control.";
RL   Nature 520:307-311(2015).
//
RX   PubMed=25984343; DOI=10.1038/sdata.2014.35;
RA   Cowley G.S., Weir B.A., Vazquez F., Tamayo P., Scott J.A., Rusin S.,
RA   East-Seletsky A., Ali L.D., Gerath W.F.J., Pantel S.E., Lizotte P.H.,
RA   Jiang G.-Z., Hsiao J., Tsherniak A., Dwinell E., Aoyama S., Okamoto M.,
RA   Harrington W., Gelfand E.T., Green T.M., Tomko M.J., Gopal S.,
RA   Wong T.C., Li H.-B., Howell S., Stransky N., Liefeld T., Jang D.,
RA   Bistline J., Meyers B.H., Armstrong S.A., Anderson K.C.,
RA   Stegmaier K., Reich M., Pellman D., Boehm J.S., Mesirov J.P.,
RA   Golub T.R., Root D.E., Hahn W.C.;
RT   "Parallel genome-scale loss of function screens in 216 cancer cell
RT   lines for the identification of context-specific genetic
RT   dependencies.";
RL   Sci. Data 1:140035-140035(2014).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S.,
RA   Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P.,
RA   Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H.,
RA   Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=27750403; DOI=10.1002/gcc.22430;
RA   Palau A., Mallo M., Palomo L., Rodriguez-Hernandez I., Diesch J.,
RA   Campos D., Granada I., Junca J., Drexler H.G., Sole F., Buschbeck M.;
RT   "Immunophenotypic, cytogenetic, and mutational characterization of
RT   cell lines derived from myelodysplastic syndrome patients after
RT   progression to acute myeloid leukemia.";
RL   Genes Chromosomes Cancer 56:243-252(2017).
//
RX   PubMed=28052028; DOI=10.18632/oncotarget.14342;
RA   Hur E.-H., Jung S.-H., Goo B.-K., Moon J., Choi Y., Choi D.R.,
RA   Chung Y.-J., Lee J.-H.;
RT   "Establishment and characterization of hypomethylating agent-resistant
RT   cell lines, MOLM/AZA-1 and MOLM/DEC-5.";
RL   Oncotarget 8:11748-11762(2017).
//
RX   PubMed=28109323; DOI=10.1186/s13045-017-0396-0;
RA   Masetti R., Bertuccio S.N., Astolfi A., Chiarini F., Lonetti A.,
RA   Indio V., De Luca M., Bandini J., Serravalle S., Franzoni M.,
RA   Pigazzi M., Martelli A.M., Basso G., Locatelli F., Pession A.;
RT   "Hh/Gli antagonist in acute myeloid leukemia with CBFA2T3-GLIS2 fusion
RT   gene.";
RL   J. Hematol. Oncol. 10:26.1-26.5(2017).
//
RX   PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005;
RA   Li J., Zhao W., Akbani R., Liu W.-B., Ju Z.-L., Ling S.-Y., Vellano C.P.,
RA   Roebuck P., Yu Q.-H., Eterovic A.K., Byers L.A., Davies M.A., Deng W.-L.,
RA   Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D.,
RA   Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y.-L., Mills G.B.,
RA   Liang H.;
RT   "Characterization of human cancer cell lines by reverse-phase protein
RT   arrays.";
RL   Cancer Cell 31:225-239(2017).
//
RX   PubMed=29491412; DOI=10.1038/s41388-018-0150-2;
RA   Gerlach D., Tontsch-Grunt U., Baum A., Popow J., Scharn D.,
RA   Hofmann M.H., Engelhardt H., Kaya O., Beck J., Schweifer N.,
RA   Gerstberger T., Zuber J., Savarese F., Kraut N.;
RT   "The novel BET bromodomain inhibitor BI 894999 represses
RT   super-enhancer-associated transcription and synergizes with CDK9
RT   inhibition in AML.";
RL   Oncogene 37:2687-2701(2018).
//
RX   PubMed=30285677; DOI=10.1186/s12885-018-4840-5;
RA   Tan K.-T., Ding L.-W., Sun Q.-Y., Lao Z.-T., Chien W., Ren X.,
RA   Xiao J.-F., Loh X.-Y., Xu L., Lill M., Mayakonda A., Lin D.-C., Yang H.,
RA   Koeffler H.P.;
RT   "Profiling the B/T cell receptor repertoire of lymphocyte derived cell
RT   lines.";
RL   BMC Cancer 18:940.1-940.13(2018).
//
RX   PubMed=30629668; DOI=10.1371/journal.pone.0210404;
RA   Uphoff C.C., Pommerenke C., Denkmann S.A., Drexler H.G.;
RT   "Screening human cell lines for viral infections applying RNA-Seq data
RT   analysis.";
RL   PLoS ONE 14:E0210404-E0210404(2019).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=31068700; DOI=10.1038/s41586-019-1186-3;
RA   Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C.,
RA   McDonald E.R. III, Barretina J.G., Gelfand E.T., Bielski C.M., Li H.-X.,
RA   Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F.,
RA   Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R.,
RA   Lu Y.-L., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C.,
RA   Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A.,
RA   Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D.,
RA   Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L.,
RA   Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A.,
RA   Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D.,
RA   Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M.,
RA   Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R.,
RA   Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A.,
RA   Sellers W.R.;
RT   "Next-generation characterization of the Cancer Cell Line
RT   Encyclopedia.";
RL   Nature 569:503-508(2019).
//
RX   PubMed=31160637; DOI=10.1038/s41598-019-44491-x;
RA   Quentmeier H., Pommerenke C., Dirks W.G., Eberth S., Koeppel M.,
RA   MacLeod R.A.F., Nagel S., Steube K., Uphoff C.C., Drexler H.G.;
RT   "The LL-100 panel: 100 cell lines for blood cancer studies.";
RL   Sci. Rep. 9:8218-8218(2019).
//
RX   PubMed=31978347; DOI=10.1016/j.cell.2019.12.023;
RA   Nusinow D.P., Szpyt J., Ghandi M., Rose C.M., McDonald E.R. III,
RA   Kalocsay M., Jane-Valbuena J., Gelfand E.T., Schweppe D.K.,
RA   Jedrychowski M.P., Golji J., Porter D.A., Rejtar T., Wang Y.K.,
RA   Kryukov G.V., Stegmeier F., Erickson B.K., Garraway L.A.,
RA   Sellers W.R., Gygi S.P.;
RT   "Quantitative proteomics of the Cancer Cell Line Encyclopedia.";
RL   Cell 180:387-402.e16(2020).
//
RX   PubMed=33669837; DOI=10.3390/ijms22042076;
RA   Janotka L., Messingerova L., Simonicova K., Kavcova H., Elefantova K.,
RA   Sulova Z., Breier A.;
RT   "Changes in apoptotic pathways in MOLM-13 cell lines after induction
RT   of resistance to hypomethylating agents.";
RL   Int. J. Mol. Sci. 22:2076.1-2076.24(2021).
//
RX   PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010;
RA   Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N.,
RA   Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J.,
RA   Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L.,
RA   Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S.,
RA   Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B.,
RA   Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.;
RT   "Pan-cancer proteomic map of 949 human cell lines.";
RL   Cancer Cell 40:835-849.e8(2022).
//